TY - JOUR T1 - Cigarettes smoked among daily and non-daily smokers following CVS Health’s tobacco-free pharmacy policy JF - Tobacco Control JO - Tob Control SP - 25 LP - 31 DO - 10.1136/tobaccocontrol-2020-055976 VL - 31 IS - 1 AU - Aryn Z Phillips AU - Jennifer A Ahern AU - William C Kerr AU - Hector P Rodriguez Y1 - 2022/01/01 UR - http://tobaccocontrol.bmj.com/content/31/1/25.abstract N2 - Introduction In September 2014, CVS Health ceased tobacco sales in all of its 7700 pharmacies nationwide. We investigate the impact of the CVS policy on the number of cigarettes smoked per day among metropolitan daily and non-daily smokers, who may respond to the availability of smoking cues in different manners.Methods Data are from the US Census Bureau Tobacco Use Supplement to the Current Population Survey 2014–2015 and the Blue Cross and Blue Shield Institute Community Health Management Hub. Adjusted difference-in-difference (DID) regressions assess changes in the number of cigarettes smoked per day among daily smokers (n=10 759) and non-daily smokers (n=3055), modelling core-based statistical area (CBSA) level CVS pharmacy market share continuously. To assess whether the policy had non-linear effects across the distribution of CVS market share, we also examine market share using tertiles.Results CVS’s tobacco-free pharmacy policy was associated with a significant reduction in the number of cigarettes smoked by non-daily smokers in the continuous DID (rate ratio=0.985, p=0.022), with a larger reduction observed among non-daily smokers in CBSAs in the highest third of CVS market share compared with those living in CBSAs with no CVS presence (rate ratio=0.706, p=0.027). The policy, however, was not significantly associated with differential changes in the number of cigarettes by daily smokers.Conclusion The removal of tobacco products from CVS pharmacies was associated with a reduction in the number of cigarettes smoked per day among non-daily smokers in metropolitan CBSAs, particularly those in which CVS had a large pharmacy market share.Data may be obtained from a third party and are not publicly available. Some data used for this analysis were proprietary and provided by Blue Cross Blue Shield Institute under a data use agreement. ER -